ArticleScientific reports2026
Ten-year hip and knee arthroplasty implant survival in patients with inflammatory arthritis receiving methotrexate monotherapy compared with osteoarthritis: a registry-based data linkage study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the 10-year risk of revision surgery following total hip (THA) and knee (TKA) arthroplasty in patients with inflammatory arthritis (IA) receiving perioperative methotrexate (MTX) monotherapy and to compare their outcomes with those of propensity score–matched patients undergoing arthroplasty for osteoarthritis. We conducted a retrospective study using data from the Emilia-Romagna Orthopedic Arthroplasty Implants Register. The primary cohort included patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis residing in Emilia-Romagna (Italy) who underwent primary THA or TKA and received at least one prescription of MTX within 90 days before or after surgery. The control cohort consisted of propensity score-matched patients who underwent THA/TKA for osteoarthritis. The perioperative MTX-treated IA group included 225 patients who underwent THA and 215 patients who underwent TKA. The control group consisted of 449 patients with osteoarthritis who received THA and 428 patients who received TKA. Implant survival rates at 10 years were not significantly different when comparing IA patients perioperatively treated with MTX monotherapy and matched osteoarthritis patients, in either those who underwent THA or TKA. This remained consistent when accounting for competing risk of death. These findings suggest that patients with IA receiving perioperative MTX monotherapy have 10-year revision outcomes comparable to those of propensity score–matched patients with osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.